世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Gamma Knife Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The Gamma Knife market is poised for a robust expansion, with projections estimating the market will grow from USD 205 million in 2025 to USD 301 million by 2032. This marks a compound annual growt... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Gamma Knife market is poised for a robust expansion, with projections estimating the market will grow from USD 205 million in 2025 to USD 301 million by 2032. This marks a compound annual growth rate (CAGR) of 5.64% over the forecast period. The market’s momentum is attributed to the rising prevalence of neurological and cognitive disorders, increasing demand for minimally invasive treatment options, and advancements in stereotactic radiosurgery technologies.Market Insights Gamma Knife technology, a form of stereotactic radiosurgery, is gaining prominence due to its precision, effectiveness, and ability to treat complex brain conditions without incisions. The treatment leverages focused gamma radiation to target and eliminate tumors or abnormalities within the brain, offering a safer alternative to traditional surgical procedures. A significant share of Gamma Knife procedures is dedicated to treating the head region, reflecting the device’s core application in neurosurgery. The technique’s ability to minimize damage to surrounding healthy tissues makes it ideal for treating brain tumors, arteriovenous malformations, and other neurological conditions. The increasing shift towards non-invasive procedures is further enhancing adoption among patients and healthcare providers alike. Key Market Drivers One of the major drivers of growth in the Gamma Knife market is the increasing prevalence of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, brain tumors, and epilepsy. As the global population ages, the incidence of these conditions is rising. According to demographic projections, one in six people worldwide will be over the age of 65 by 2050, compared to one in eleven in 2019. In addition, the rise in brain cancer cases globally is intensifying the need for effective and less intrusive treatment methods. Gamma Knife radiosurgery, with its proven efficacy and reduced recovery time, is emerging as a preferred choice for many patients and clinicians. Business Opportunity Growing awareness about the advantages of Gamma Knife technology—such as its non-invasive nature, fewer side effects, and quick recovery—is opening new business opportunities, especially in emerging economies. Technological innovation is also contributing significantly to market expansion. Companies are focusing on developing systems that allow for improved treatment planning, patient comfort, and integration with advanced imaging technologies. Combination therapies are becoming more popular, especially for treating metastatic brain conditions. For instance, integrating Gamma Knife radiosurgery with immunotherapy has shown promising results in treating complex cases like melanoma brain metastases, boosting demand for advanced stereotactic systems. Regional Analysis The U.S. continues to lead the global Gamma Knife market due to high healthcare spending, a rising number of cancer cases, and early adoption of innovative treatments. With a high incidence of brain and neurological disorders, the country is a critical contributor to global market revenue. Germany is another significant market, driven by the increasing number of Alzheimer’s disease cases and continuous technological advancements in the country’s healthcare infrastructure. Companies are actively investing in R&D and collaborating with academic institutions to improve existing treatment modalities. Japan is witnessing notable growth owing to the rising prevalence of vascular abnormalities and its highly developed healthcare system. The country’s focus on advanced medical technologies and growing awareness among patients are contributing to its expanding market share. Key Players The Gamma Knife market is competitive and innovation-driven. Major players are emphasizing mergers, acquisitions, and strategic partnerships to enhance their global footprint. Notable companies include: • Elekta AB • Varian Medical Systems • Huiheng Medical, Inc. • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd. • Akesis Inc. • Cyber Medical Corporation Limited • Masep Infini Global, Inc. • Nordion, Inc. • Hokai • ET Medical Group • American Shared Hospital Services These companies are consistently investing in product innovation and regulatory approvals to gain a competitive edge. Market Segmentation By Disease Indication: • Brain Metastasis • Cancer • Arteriovenous Malformation (AVM) • Trigeminal Neuralgia • Others By Organ Treated: • Head • Neck • Others By Region: • North America • Latin America • Europe • South Asia • East Asia • Oceania • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Gamma Knife Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Gamma Knife Market Outlook, 2019-2032 3.1. Global Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Brain Metastasis 3.1.1.2. Cancer 3.1.1.3. Arteriovenous Malformation (AVM) 3.1.1.4. Trigeminal Neuralgia 3.1.1.5. Others 3.2. Global Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Head 3.2.1.2. Neck 3.2.1.3. Others 3.3. Global Gamma Knife Market Outlook, by Region, Value (US$ Mn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Gamma Knife Market Outlook, 2019-2032 4.1. North America Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Brain Metastasis 4.1.1.2. Cancer 4.1.1.3. Arteriovenous Malformation (AVM) 4.1.1.4. Trigeminal Neuralgia 4.1.1.5. Others 4.2. North America Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Head 4.2.1.2. Neck 4.2.1.3. Others 4.3. North America Gamma Knife Market Outlook, by Country, Value (US$ Mn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 4.3.1.2. U.S. Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 4.3.1.3. Canada Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 4.3.1.4. Canada Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Gamma Knife Market Outlook, 2019-2032 5.1. Europe Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Brain Metastasis 5.1.1.2. Cancer 5.1.1.3. Arteriovenous Malformation (AVM) 5.1.1.4. Trigeminal Neuralgia 5.1.1.5. Others 5.2. Europe Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Head 5.2.1.2. Neck 5.2.1.3. Others 5.3. Europe Gamma Knife Market Outlook, by Country, Value (US$ Mn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.2. Germany Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.3. U.K. Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.4. U.K. Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.5. France Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.6. France Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.7. Italy Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.8. Italy Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.9. Turkey Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.10. Turkey Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.11. Russia Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.12. Russia Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.1.13. Rest of Europe Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 5.3.1.14. Rest of Europe Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Gamma Knife Market Outlook, 2019-2032 6.1. Asia Pacific Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Brain Metastasis 6.1.1.2. Cancer 6.1.1.3. Arteriovenous Malformation (AVM) 6.1.1.4. Trigeminal Neuralgia 6.1.1.5. Others 6.2. Asia Pacific Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Head 6.2.1.2. Neck 6.2.1.3. Others 6.2.2. BPS Analysis/Market Attractiveness Analysis 6.3. Asia Pacific Gamma Knife Market Outlook, by Country, Value (US$ Mn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.2. China Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.1.3. Japan Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.4. Japan Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.1.5. South Korea Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.6. South Korea Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.1.7. India Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.8. India Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.1.9. Southeast Asia Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.10. Southeast Asia Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.1.11. Rest of Asia Pacific Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 6.3.1.12. Rest of Asia Pacific Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Gamma Knife Market Outlook, 2019-2032 7.1. Latin America Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Brain Metastasis 7.1.1.2. Cancer 7.1.1.3. Arteriovenous Malformation (AVM) 7.1.1.4. Trigeminal Neuralgia 7.1.1.5. Others 7.2. Latin America Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 7.2.1.1. Head 7.2.1.2. Neck 7.2.1.3. Others 7.2.2. BPS Analysis/Market Attractiveness Analysis 7.3. Latin America Gamma Knife Market Outlook, by Country, Value (US$ Mn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 7.3.1.2. Brazil Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 7.3.1.3. Mexico Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 7.3.1.4. Mexico Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 7.3.1.5. Argentina Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 7.3.1.6. Argentina Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 7.3.1.7. Rest of Latin America Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 7.3.1.8. Rest of Latin America Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Gamma Knife Market Outlook, 2019-2032 8.1. Middle East & Africa Gamma Knife Market Outlook, by Disease Indication, Value (US$ Mn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Brain Metastasis 8.1.1.2. Cancer 8.1.1.3. Arteriovenous Malformation (AVM) 8.1.1.4. Trigeminal Neuralgia 8.1.1.5. Others 8.2. Middle East & Africa Gamma Knife Market Outlook, by Organ Treated, Value (US$ Mn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Head 8.2.1.2. Neck 8.2.1.3. Others 8.2.2. BPS Analysis/Market Attractiveness Analysis 8.3. Middle East & Africa Gamma Knife Market Outlook, by Country, Value (US$ Mn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 8.3.1.2. GCC Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 8.3.1.3. South Africa Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 8.3.1.4. South Africa Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 8.3.1.5. Egypt Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 8.3.1.6. Egypt Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 8.3.1.7. Nigeria Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 8.3.1.8. Nigeria Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Gamma Knife Market by Disease Indication, Value (US$ Mn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Gamma Knife Market by Organ Treated, Value (US$ Mn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. By Disease Indication vs by Organ Treated Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Elekta AB 9.4.1.1. Company Overview 9.4.1.2. Therapy Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Development 9.4.2. Varian Medical Systems 9.4.2.1. Company Overview 9.4.2.2. Therapy Portfolio 9.4.2.3. Financial Overview 9.4.2.4. Business Strategies and Development 9.4.3. Huiheng Medical, Inc. 9.4.3.1. Company Overview 9.4.3.2. Therapy Portfolio 9.4.3.3. Financial Overview 9.4.3.4. Business Strategies and Development 9.4.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd. 9.4.4.1. Company Overview 9.4.4.2. Therapy Portfolio 9.4.4.3. Financial Overview 9.4.4.4. Business Strategies and Development 9.4.5. Akesis Inc. 9.4.5.1. Company Overview 9.4.5.2. Therapy Portfolio 9.4.5.3. Financial Overview 9.4.5.4. Business Strategies and Development 9.4.6. Cyber Medical Corporation Limited. 9.4.6.1. Company Overview 9.4.6.2. Therapy Portfolio 9.4.6.3. Financial Overview 9.4.6.4. Business Strategies and Development 9.4.7. Masep Infini Global, Inc. 9.4.7.1. Company Overview 9.4.7.2. Therapy Portfolio 9.4.7.3. Financial Overview 9.4.7.4. Business Strategies and Development 9.4.8. Nordion, Inc. 9.4.8.1. Company Overview 9.4.8.2. Therapy Portfolio 9.4.8.3. Financial Overview 9.4.8.4. Business Strategies and Development 9.4.9. Hokai 9.4.9.1. Company Overview 9.4.9.2. Therapy Portfolio 9.4.9.3. Financial Overview 9.4.9.4. Business Strategies and Development 9.4.10. ET Medical Group 9.4.10.1. Company Overview 9.4.10.2. Therapy Portfolio 9.4.10.3. Financial Overview 9.4.10.4. Business Strategies and Development 9.4.11. American Shared Hospital Services 9.4.11.1. Company Overview 9.4.11.2. Therapy Portfolio 9.4.11.3. Financial Overview 9.4.11.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Fairfield Market Research社の 医療機器分野 での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
